Examples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries

Hdl Handle:
http://hdl.handle.net/10144/618813
Title:
Examples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries
Authors:
Guglielmetti, L; Hewison, C; Avaliani, Z; Hughes, J; Kiria, N; Lomtadze, N; Ndjeka, N; Setkina, S; Shabangu, A; Sikhondze, W; Skrahina, A; Veziris, N; Furin, J
Journal:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
Abstract:
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.
Publisher:
International Union Against Tuberculosis and Lung Disease
Issue Date:
1-Feb-2017
URI:
http://hdl.handle.net/10144/618813
DOI:
10.5588/ijtld.16.0493
PubMed ID:
28234080
Additional Links:
https://www.ncbi.nlm.nih.gov/pubmed/28234080
Submitted date:
2017-02-27
Language:
en
Description:
Abstract available only, full article is not open access. To access this article click on "additional links".
ISSN:
1815-7920
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorGuglielmetti, Len
dc.contributor.authorHewison, Cen
dc.contributor.authorAvaliani, Zen
dc.contributor.authorHughes, Jen
dc.contributor.authorKiria, Nen
dc.contributor.authorLomtadze, Nen
dc.contributor.authorNdjeka, Nen
dc.contributor.authorSetkina, Sen
dc.contributor.authorShabangu, Aen
dc.contributor.authorSikhondze, Wen
dc.contributor.authorSkrahina, Aen
dc.contributor.authorVeziris, Nen
dc.contributor.authorFurin, Jen
dc.date.accessioned2017-02-28T21:31:58Z-
dc.date.available2017-02-28T21:31:58Z-
dc.date.issued2017-02-01-
dc.date.submitted2017-02-27-
dc.identifier.citationExamples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries. 2017, 21 (2):167-174 Int. J. Tuberc. Lung Dis.en
dc.identifier.issn1815-7920-
dc.identifier.pmid28234080-
dc.identifier.doi10.5588/ijtld.16.0493-
dc.identifier.urihttp://hdl.handle.net/10144/618813-
dc.descriptionAbstract available only, full article is not open access. To access this article click on "additional links".en
dc.description.abstractFor the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.en
dc.language.isoenen
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/28234080en
dc.rightsArchived with thanks to The international Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Diseaseen
dc.titleExamples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countriesen
dc.identifier.journalThe International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Diseaseen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.